Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (vascular smooth muscle cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: pecavaptan, argipressin tannate, balovaptan +10 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4708
Sealed predictions
- AVPR1A in dopamine neurons, braak+0.12 (p 0.756) → +0.40 (p 0.285)receipt 4712
Swarm cases
receipt 4712: AVPR1A in dopamine neurons, braak
- power
- full sample +0.36 (p 0.140, n 18), 95% CI -0.13 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.120, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.114, n 18). could be the mix.
- skeptic
- leave-one-out range +0.27 to +0.56, sign flips 0; without severely affected donors +0.36 (p 0.140, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AVPR1A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts